Search results for "real-world"

showing 10 items of 49 documents

Real-life assessment of chronic rhinosinusitis patients using mobile technology: the mySinusitisCoach project by EUFOREA

2020

Abstract Background Chronic rhinosinusitis (CRS) is a chronic inflammatory disease associated with a substantial personal and socioeconomic burden. Monitoring of patient‐reported outcomes by mobile technology offers the possibility to better understand real‐life burden of CRS. Methods This study reports on the cross‐sectional evaluation of data of 626 users of mySinusitisCoach (mSC), a mobile application for CRS patients. Patient characteristics of mSC users were analysed as well as the level of disease control based on VAS global rhinosinusitis symptom score and adapted EPOS criteria. Results The mSC cohort represents a heterogeneous group of CRS patients with a diverse pattern of major sy…

Aplicacions mòbilsSYMPTOMSSinusititsvisual analogue scale0302 clinical medicineQuality of lifeMedicine and Health SciencesImmunology and AllergyNasal polyps030223 otorhinolaryngologyRhinitisnasal polypreal‐world evidenceASSOCIATION3. Good healthPREVALENCEALLERGIC RHINITISpatient-reported outcome measureCohortOriginal Articlepatient‐reported outcome measureENDOSCOPIC SINUS SURGERYmedicine.medical_specialtyVisual analogue scaleImmunologyMobile health technology03 medical and health sciencesNasal PolypsInternal medicinemedicineotorhinolaryngologic diseasesHumansNASALSinusitisreal-world evidenceDisease burdenMobile health technology; nasal polyp; patient-reported outcome measure; real-world evidence; visual analogue scaleTelecommunication in medicineAsthmabusiness.industryRhinitis Sinusitis and Upper Airway DiseaseFunctional endoscopic sinus surgerymedicine.diseasePrecision medicineSEVERITYCross-Sectional Studies030228 respiratory system3121 General medicine internal medicine and other clinical medicineChronic DiseaseMobile appsQuality of LifeASTHMAHuman medicineORIGINAL ARTICLESVISUAL ANALOG SCALEbusinessTelecomunicació en medicina
researchProduct

An evaluation of the estimation of road traffic emission factors from tracer studies

2010

Road traffic emission factors (EFs) are one of the main sources of uncertainties in emission inventories; it is necessary to develop methods to reduce these uncertainties to manage air quality more efficiently. Recently an alternative method has been proposed to estimate the EFs. In that work the emission factors were estimated from a long term tracer study developed in Ho Chi Minh City (HCMC) Vietnam. A passive tracer was continuously emitted from a finite line source placed in one side of an urban street canyon. Simultaneously, the resulting tracer concentrations were monitored at the other side of the street. The results of this experiment were used to calculate the dispersion factors an…

Atmospheric Sciencemodel validationPart Ii010504 meteorology & atmospheric sciencesMeteorologyStreet CanyonsField010501 environmental sciencesComputational fluid dynamics01 natural sciencesLine sourceDispersion ModelsPollutant DispersionTRACER11. SustainabilityRange (statistics)Statistical dispersionEmission inventoryAir quality index0105 earth and related environmental sciencesGeneral Environmental ScienceWind tunneltracer studiesFlowbusiness.industrystreet canyon[SHS.GEO]Humanities and Social Sciences/GeographyAir-QualityParticles13. Climate actionEnvironmental scienceWind-TunnelbusinessSimulationreal-world motor vehicle emissionsComputational Fluids Dynamics (CFD)
researchProduct

Prey-predator strategies in a multiagent system

2006

This paper describes the prey-predator multiagent system which can be considered as an abstraction of more complex real-world models. Both the prey and the predators are considered as autonomous agents with their own behaviors and perception of the environment. In particular, we propose a simulator which lets study different strategies such as cooperation and individualism. An extensive experiment has been carried out in order to prove the effectiveness of the latter.

Autonomous agentLarge scale systemSettore INF/01 - InformaticaComputer sciencebusiness.industrymedia_common.quotation_subjectMulti-agent systemAutonomous agentReal-world systemcomputer.software_genreComputingMethodologies_ARTIFICIALINTELLIGENCEAgent-based social simulationPredationIntelligent agentPerceptionPrey-predator strategiePrey predatorArtificial intelligencebusinesscomputerMulti agent systemsmedia_commonAbstraction (linguistics)
researchProduct

A real-world economic analysis of biologic therapies for psoriatic arthritis in Italy: results of the CHRONOS observational longitudinal study

2022

Abstract Background Psoriatic arthritis (PsA) is a chronic, immune-mediated, spondyloarthropathy characterised by musculoskeletal signs and symptoms with associated joint pain and tenderness. The average worldwide PsA prevalence is 133/100,000, while in the Italian population is 90–420/100,000. Traditionally, nonsteroidal anti-inflammatory drugs, glucocorticoid, and disease-modifying antirheumatic drugs have been used in the treatment of PsA. However, for those patients who are not adequately controlled with conventional therapies, the new biologics compounds represent a valid option. Biologic therapies have been shown to be more effective but also more expensive than conventional systemic …

Biological ProductsBiologicCostHealth PolicyArthritis PsoriaticPsoriatic arthritiTumor necrosis factor.Cost-per-responderBiological TherapyTreatment OutcomeReal-worldAntirheumatic AgentsHumansLongitudinal StudiesSecukinumabBMC Health Services Research
researchProduct

Predictors of early discontinuation of dapagliflozin versus other glucose-lowering medications: a retrospective multicenter real-world study

2020

Background and aims: In routine clinical practice, early discontinuation of newly initiated glucose-lowering medications (GLM) is relatively common. We herein evaluated if the clinical characteristics associated with early discontinuation of dapagliflozin were different from those associated with early discontinuation of other GLM. Methods: The DARWIN-T2D was a multicenter retrospective study conducted at diabetes specialist outpatient clinics in Italy. We included 2484 patients who were initiated on dapagliflozin in 2015–2016 and 14,801 patients who were initiated on other GLM (DPP-4 inhibitors, GLP-1 receptor agonists, or gliclazide) in the same period. After excluding patients who had no…

Blood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismType 2 diabetes03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyGlucosidesDiabetes mellitusInternal medicineAdherence; Observational; Pharmacotherapy; Real-world; Type 2 diabetes; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Retrospective Studies; Withholding TreatmentDiabetes MellitusmedicineHumansHypoglycemic AgentsOutpatient clinicBenzhydryl CompoundsDapagliflozinObservationalAgedRetrospective StudiesDipeptidyl-Peptidase IV InhibitorsAdherence; Observational; Pharmacotherapy; Real-world; Type 2 diabetesbusiness.industryType 2 diabetesRetrospective cohort studyMiddle Agedmedicine.diseasePharmacotherapyMetforminDiscontinuationDiabetes Mellitus Type 2Real-worldWithholding TreatmentchemistryTolerabilityAdherence030220 oncology & carcinogenesisFemalebusinessType 2medicine.drugJournal of Endocrinological Investigation
researchProduct

Refining sorafenib therapy: lessons from clinical practice

2015

ABSTRACT  Understanding the best use of sorafenib is essential in order to maximize clinical benefit in hepatocellular carcinoma. Based on Phase III and noninterventional study data, as well as our extensive experience, we discuss dose modification in order to manage adverse events, disease response evaluation and how to maximize treatment benefit. Sorafenib should be initiated at the approved dose (400 mg twice daily) and reduced/interrupted as appropriate in order to manage adverse events. Dose modification should be considered before discontinuation. Appropriate tumor response assessment is critical. Focusing on radiologic response may result in premature sorafenib discontinuation; symp…

Cancer ResearchSettore SECS-P/06 - Economia ApplicataAntineoplastic AgentAge FactorChild–Pugh Bpostprogression treatmentresponse assessmentdose modificationClinical Trials as TopicLiver Neoplasmsadverse event managementAge FactorsChild-Pugh Bpostprogression treatmenthepatocellular carcinomaGeneral MedicinePrognosisadverse event management; child–Pugh B; dose modification; elderly hepatocellular carcinoma; mRECIST; postprogression treatment; eal-world data; response assessment; sorafenibelderly hepatocellular carcinomaCombined Modality Therapychild–Pugh BClinical PracticeTreatment OutcomeOncologyLiver Neoplasmeal-world dataHepatocellular carcinomaadverse event managementRetreatmentDisease Progressiondose modificationHumanmedicine.drugPhenylurea CompoundNiacinamideSorafenibmedicine.medical_specialtyCarcinoma HepatocellularDisease ResponsePrognosielderly hepatocellular carcinomaProtein Kinase InhibitorAntineoplastic AgentsmRECISTelderlymRECISTAdverse event management Child–Pugh B dose modification elderly hepatocellular carcinoma mRECIST postprogression treatment real-world data response assessment sorafenibmedicineChild–Pugh BHumansCombined Modality TherapyIntensive care medicineAdverse effectProtein Kinase InhibitorsDose Modificationreal-world databusiness.industryPhenylurea Compoundsmedicine.diseaseDiscontinuationSurgeryreal-world dataresponse assessmentsorafenibbusinessFuture Oncology
researchProduct

KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer

2022

Background: KRAS mutations, present in over 40% of metastatic colorectal cancer (mCRC), are negative predictive factors for anti-EGFR therapy. Mutations in KRAS-G12C have a cysteine residue for which drugs have been developed. Published data on this specific mutation are conflicting; thus, we studied the frequency and clinical characteristics in a real-world and population-based setting. Methods: Patients from three Nordic population-based cohorts and the real-life RAXO-study were combined. RAS and BRAF tests were performed in routine healthcare, except for one cohort. The dataset consisted of 2,559 patients, of which 1,871 could be accurately classified as KRAS, NRAS, and BRAF-V600E. Demog…

Cancer och onkologireal-worldendocrine system diseasesEGFR3122 CancersKRAS mutationKRAS-G12C mutationKRAS MUTATIONScolorectal cancersuolistosyövät3126 Surgery anesthesiology intensive care radiologyTUMORSdigestive system diseasesetäpesäkkeetmetastaticpopulation-basedPOOLED ANALYSISRAS MUTATIONSsyöpägeenitCancer and Oncologymutaatiotkohorttitutkimusneoplasmspaksusuolisyöpä
researchProduct

Cerebral Dynamics during the Observation of Point-Light Displays Depicting Postural Adjustments

2017

Objective: As highly social creatures, human beings rely part of their skills of identifying, interpreting, and predicting the actions of others on the ability of perceiving biological motion. In the present study, we aim to investigate the electroencephalographic (EEG) cerebral dynamics involved in the coding of postural control and examine whether upright stance would be codified through the activation of the temporal-parietal cortical network classically enrolled in the coding of biological motion. Design: We registered the EEG activity of 12 volunteers while they passively watched point light displays (PLD) depicting quiet stable (QB) and an unstable (UB) postural situations and their r…

Ciencias Físicasbiological motion perceptionElectroencephalographyaction observationneural mechanismsevent-related potentials//purl.org/becyt/ford/1 [https]Behavioral Neuroscience0302 clinical medicinebrain activitySUPERIOR TEMPORAL SULCUSPostural Balancevisual-perceptionbody swayPOINT-LIGHT DISPLAYOriginal Researchmedicine.diagnostic_testsemantic integration05 social sciencesCognitionSuperior temporal sulcusPsychiatry and Mental healthNeuropsychology and Physiological PsychologyACTION OBSERVATIONNeurologyBALANCEQUIETELECTROENCEPHALOGRAPHY[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]recognitionPsychologysuperior temporal sulcusCIENCIAS NATURALES Y EXACTASelectroencephalographymedicine.medical_specialtyOtras Ciencias Físicas050105 experimental psychologylcsh:RC321-57103 medical and health sciencesPhysical medicine and rehabilitationmotor imagerymedicine0501 psychology and cognitive scienceslcsh:Neurosciences. Biological psychiatry. NeuropsychiatryBiological PsychiatryBalance (ability)Communicationbusiness.industrybalance//purl.org/becyt/ford/1.3 [https]point-light display[ SDV.NEU ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]business030217 neurology & neurosurgeryNeuroscienceBiological motionCoding (social sciences)real-world events
researchProduct

Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A met…

2017

The direct-acting antiviral regimen of ombitasvir (OBV)/paritaprevir (PTV)/ritonavir (r) ± dasabuvir (DSV) ± ribavirin (RBV) demonstrated high rates of sustained viral response at post-treatment week 12 (SVR12) in clinical trials for treatment of hepatitis C virus (HCV) genotypes (GT) 1 and 4. To confirm the effectiveness of this regimen in the real world, we conducted meta-analyses of published literature on 30 April 2016. Freeman-Tukey transformation determined the SVR rate within GTs 1a, 1b, and 4, as well as specific SVR rates by cirrhosis or prior treatment experience status. Rates of virologic relapse, hepatic decompensation, drug discontinuation, and serious adverse events were also …

CyclopropanesLiver CirrhosisSustained Virologic ResponseHCV genotypes 1 and 4ComorbidityHepacivirusmedicine.disease_causeGastroenterologymeta-analysichemistry.chemical_compound0302 clinical medicineAnilides030212 general & internal medicineSulfonamidesDasabuvirValineHepatitis CViral LoadHepatitis Creal-world effectiveneInfectious DiseasesTreatment Outcome2D; 3D; HCV genotypes 1 and 4; hepatitis C; meta-analysis; real-world effectiveness; Hepatology; Infectious Diseases; Virology030211 gastroenterology & hepatologyDrug Therapy Combinationmedicine.drug3Dmedicine.medical_specialtyMacrocyclic CompoundsGenotypeProlineHepatitis C virusLactams MacrocyclicInfectious DiseaseAntiviral Agents03 medical and health sciencesInternal medicineVirologyRibavirinmedicineHumans2DRitonavirHepatologybusiness.industryRibavirinmedicine.diseaseOmbitasvirRegimenchemistryParitaprevirImmunologyRitonavirCarbamatesbusinessJournal of viral hepatitis
researchProduct

Real-world evidence from a European cohort study of patients with treatment resistant depression:Healthcare resource utilization

2022

Journal of affective disorders 298, Part A 442-450 (2022). doi:10.1016/j.jad.2021.11.004 special issue: "Special Issue on Corona Virus / Edited by Allan Young, Ron Acierno, Xiang Yang Zhang"

Healthcare resource utilization Major depressive disorder Observational study Real-world evidence Treatment resistant depressionmedicine.medical_specialtyMajor depressive disorderTreatment resistant depressionCohort StudiesIndirect costsDepressive Disorder Treatment-ResistantHealthcare resource utilization; Major depressive disorder; Observational study; Real-world evidence; Treatment resistant depressionObservational studyHealth careHealthcare resource utilizationmedicineHumansMajor depressive episodeDepression (differential diagnoses)Retrospective StudiesReal-world evidenceDepressive DisorderDepressive Disorder Majorbusiness.industryTreatment-ResistantMajorHealth Care Costsmedicine.diseasePsychiatry and Mental healthClinical PsychologyEmergency medicineMajor depressive disorderObservational studymedicine.symptombusinessHealthcare resource utilization; Major depressive disorder; Observational study; Real-world evidence; Treatment resistant depression; Cohort Studies; Delivery of Health Care; Health Care Costs; Humans; Retrospective Studies; Depressive Disorder Major; Depressive Disorder Treatment-ResistantTreatment-resistant depressionDelivery of Health CareCohort study
researchProduct